NASHVILLE, Tenn. — January 6, 2026 — Leads & Copy — Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) has appointed Dr. Nick Ioannou, M.D., MHA, as Vice President of Medical Affairs.
Dr. Ioannou brings over three decades of experience in clinical practice, diagnostics, regulatory affairs, medical education, and medical affairs. His background includes more than 15 years of collaboration with key opinion leaders across organ transplantation, nephrology, cardiology, pulmonology, genetics, and oncology.
Before joining Insight Molecular Diagnostics, Dr. Ioannou served as a senior staff medical science liaison and field director at Guardant Health. He has also held senior medical affairs positions at Natera, LA Ort Institute, L-Nutra, and CSL Behring, as well as roles at Fresenius, Baxter, and Northwestern University.
According to Insight Molecular Diagnostics, Dr. Ioannou’s experience as a medical director and partner in private clinics has allowed him to connect with patients, families, physicians, nurses, and other healthcare partners.
iMDx CEO Josh Riggs stated that Dr. Ioannou’s medical advisory experience in organ transplant, nephrology, cardiology, oncology, and genetics makes him a good fit for the company. Riggs added that the company is looking forward to Dr. Ioannou’s expertise as iMDx launches its first commercial products.
Dr. Ioannou said he is excited to join iMDx and believes the market needs a better transplant rejection testing paradigm. He looks forward to helping deliver valuable diagnostics for hospital colleagues and their patients.
Dr. Ioannou holds a Bachelor of Science in Microbiology from California State University, Northridge, and a Master of Healthcare Administration from Saint Joseph’s College of Maine. He completed his Medical Doctorate clinical training at Michael Reese Hospital in Chicago.
Insight Molecular Diagnostics aims to democratize access to molecular diagnostic testing to improve patient outcomes.
GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Insight Molecular Diagnostics Inc.
Contact: Doug Farrell, LifeSci Advisors LLC, dfarrell@lifesciadvisors.com
Source: Insight Molecular Diagnostics Inc.
